STAT

Months after a sexual harassment scandal, OrbiMed’s banking another billion

Months after being rocked by sexual harassment allegations, biotech’s largest investment fund is in process of raising $1 billion from investors, its largest offering to date, while the founder who was at the center of the controversy remains a partner at the firm.

Legendary biotech financier Sam Isaly said late last year that he would retire following publication of a STAT investigation in which six former OrbiMed employees said he regularly sexually harassed the firm’s female employees, particularly executive assistants.

But recent filings with the Securities. The Wall Street firm and Isaly are in the process of negotiating his departure, but it’s unclear how long those talks might take.

You're reading a preview, sign up to read more.

More from STAT

STAT2 min read
This Troubled Biotech Needed Cash, So It Turned To A Predatory Lender: Its Own CEO
I don’t write about Northwest Biotherapeutics much anymore because it’s not cool to punch down. However, there was a juicy nugget in the cancer biotech’s recently filed 10-Q that had to be shared. It’s another example of a biotech executive getting r
STAT2 min read
Top Scientist Categorically Denies Any Wrongdoing In Novartis Data Manipulation Scandal
The Novartis scientist who was ousted by the drug maker in connection with a scandal over data manipulation broke his silence.
STAT4 min readSociety
Opinion: Virtual And Augmented Reality Can Save Lives By Improving Surgeons’ Training
Rapid advances in the development of medical devices in the 21st century are contributing to healthier lives, but bring with them a new challenge: teaching clinicians how to use these often-complicated technologies. Teaching them poorly, or failing t